Skip to main content
Clinical Trials/NCT03011190
NCT03011190
Completed
Not Applicable

Effectiveness of the Iconic Therapy in Youth With Suicidal Ideation/Self-injuring Behavior and Borderline Personality Traits: Study Protocol for a Randomized Controlled Trial

Silvia Elisa Hurtado Santiago1 site in 1 country40 target enrollmentSeptember 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Personality Disorder, Borderline
Sponsor
Silvia Elisa Hurtado Santiago
Enrollment
40
Locations
1
Primary Endpoint
Change on the severity of borderline personality disorder measured by Borderline Personality Symptom List (BSL-23).
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

Borderline personality disorder (BPD) is the most prevalent personality disorder in young community population whose most severe complication is suicide. Pharmacotherapy should not be used as the primary treatment for BPD as the benefits are unclear. Psychotherapy is the main treatment for people with BPD and the current recommendation is adapting available comprehensive treatments to develop easier and briefer therapies that are also effective. Iconic Therapy is an innovative option whose good clinical results should be validated on a clinical trial.

Detailed Description

Borderline Personality Disorder (BPD) in the early adulthood is an increasing diagnosis among general population. First symptoms detection and early intervention might help prevent its aggravation and further BPD diagnosis. Iconic Therapy is an innovative manual-driven psychotherapy to specifically and intensively treat BPD symptoms. Preliminary clinical results are good. The aim of the present study is to assess the effectiveness of the Iconic Therapy in comparison to a support structured therapy in an ecological setting (Spanish public specialized mental health care). The study is planned as a randomized controlled prospective trial that will randomize 60 young people (15 to 25 years old) with suicidal ideation/self-injuring behaviour and borderline personality traits. Participants will be randomly assigned to one of the two groups: Iconic Therapy or support structured therapy on a 1:1 basis. Both the Iconic Therapy and the support therapy programs consist of 10-12 weekly sessions delivered by two trained psychologists for about 8-12 outpatients on group format. The primary outcome measure is the change of symptoms severity assessed by the Borderline Personality Disorder List (BSL-23). Secondary outcomes include suicidal ideation and behavior, non-suicidal self-injures maladjustment to the daily life and economic evaluation for health care. Assessments will be performed at baseline after the intervention 6 and 12 months of follow-up. It is hypothesized that those attending the Iconic Therapy group will show a permanently reduction of the severity of symptoms as compared with those attending the structured support group. Data will be analyzed using generalized estimating equations (GEE) models.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
December 2017
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Silvia Elisa Hurtado Santiago
Responsible Party
Sponsor Investigator
Principal Investigator

Silvia Elisa Hurtado Santiago

Principal investigator

University of Malaga

Eligibility Criteria

Inclusion Criteria

  • Aged 15-25 years old
  • Suicidal ideation and/or self-injuring behavior
  • BPD behavioural trends defined as the cut point for alarming BPD traits (\>38 score) on Exploratory Questionnaire of Personality-III-BPD (CEPER-III-BPD)
  • Sufficiently proficient in Spanish to follow the treatment

Exclusion Criteria

  • Antisocial personality disorder as measured in the Clinical Interview for Diagnostic and Statistical Manual (DSM-IV Axis II) (SCID-II)
  • Substance or alcohol abuse
  • High suicidal risk
  • Negative expectations to be enrolled in the study as measured \< 35 by the Expectation of Treatment Scale (ETS)

Outcomes

Primary Outcomes

Change on the severity of borderline personality disorder measured by Borderline Personality Symptom List (BSL-23).

Time Frame: Baseline and up to 12 months after inclusion.

This questionnaire (BSL-23) is a dimensional instrument: the most widely used to assess borderline personality disorder symptomatology improvement in clinical trials. The Spanish validated version of the questionnaire will be used.

Secondary Outcomes

  • Change on the suicidal ideation and behavior measured by the Columbia Suicide History Form (SSRS).(Baseline and up to 12 months after inclusion.)
  • Change on non-suicidal self-injure diagnosis(Baseline and up to 12 months after inclusion.)
  • Sociodemographic variables(Baseline)
  • Change on the economic evaluation measured by the Client Service Receipt Inventory (CSRI) - adapted Spanish version (CSRI-Spanish version)(Baseline and up to 12 months after inclusion.)

Study Sites (1)

Loading locations...

Similar Trials